Progress on economic burden of patients with multidrug resistant tuberculosis
10.3969/j.issn.1006-2483.2020.05.027
- VernacularTitle:耐多药结核病疾病经济负担研究进展
- Author:
Chengqiong WANG
1
;
Ling CHEN
1
Author Information
1. The Tuberculosis Inpatient Ward of Respiratory and Critical Care Medicine Department, the Affiliated hospital of Zunyi Medical University, Zunyi, Guizhou
- Publication Type:Journal Article
- Keywords:
Multidrug resistant tuberculosis;
Economic burden;
Catastrophic health expenditure
- From:
Journal of Public Health and Preventive Medicine
2020;31(5):105-108
- CountryChina
- Language:Chinese
-
Abstract:
Compared with ordinary tuberculosis, multidrug resistant tuberculosis (MDR-TB) is more difficult to treat, with longer time of regime, lower cure rate and higher cost of treatment. It is estimated that the cost of multidrug resistant tuberculosis is about 100-200 times that of ordinary tuberculosis, resulting in the catastrophic health expenditure of some patients and their families, which seriously affects the patients’ compliance with treatment, and makes effective prevention and control of tuberculosis face huge resistance. So far, only a limited number of studies have analyzed the economic burden of the disease and its impact on patients, families and societies from different perspectives. Therefore, this article systematically reviews the economic burden of MDR-TB patients, and reveals the current economic burden of MDR-TB tuberculosis and related research progress, to provide a reference for optimizing or improving relevant medical insurance policies to control the tuberculosis and also for future studies.
